FCF strives to be in the forefront of research on fibrolamellar carcinoma (FLC). Listed below are leading physicians, scientists and researchers who are experienced with FLC and have agreed to be advisors to the Fibrolamellar Cancer Foundation. Each represents an institution or laboratory which is currently involved in research or treatment of fibrolamellar liver cancer.
These advisors, working closely with FCF’s Scientific Director Mark Furth, PhD, provide strategic direction for our research programs and play a key role in guiding and prioritizing FCF’s research investments.
Medical & Scientific Advisory Board (MSAB)
| Name | Position |
|---|---|
| Ghassan Abou-Alfa, MD | Medical Oncologist Gastrointestinal Oncology Memorial Sloan Kettering Cancer Center New York, NY |
| John Gordan, MD, PhD | Assistant Professor Hematology and Oncology University of California, San Francisco (UCSF) San Francisco, CA |
| Elizabeth M. Jaffee, MD | Deputy Director, Sidney Kimmel Comprehensive Cancer Center Professor of Oncology, Bloomberg-Kimmel Institute for Immunotherapy Johns Hopkins University Baltimore, MD |
| Allison F. O’Neill, MD | Director, Pediatric Liver Tumor Program Dana-Farber Cancer Institute Boston Children’s Hospital Harvard Medical School Boston, MA |
| John D. Scott, PhD | Edwin G. Krebs – Speights Professor of Cell Signaling and Cancer Biology Chairman, Department of Pharmacology University of Washington School of Medicine Seattle, WA |
| Jessica Zucman-Rossi, MD, PhD | Professor of Oncology Director, INSERM Unit “Functional Genomics of Solid Tumors” Université Paris Descartes Paris, France |
MSAB Members Emeritus
| Name | Position |
|---|---|
| John Craig, MD, PhD | Medical Director (retired) St. Jude Medical Center Fullerton, CA Member, Board of Directors Fibrolamellar Cancer Foundation |
| Lola Reid, PhD | Professor Department of Cell Biology and Physiology University of North Carolina Chapel Hill, NC |